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Abstract
The identification and validation of biomarkers for clinical applications remains an important
issue for improving diagnostics and therapy in many diseases, including prostate cancer.
Gene expression profiles are routinely applied to identify diagnostic and predictive biomark-
ers or novel targets for cancer. However, only few predictive markers identified in silico
have also been validated for clinical, functional or mechanistic relevance in disease pro-
gression. In this study, we have used a broad, bioinformatics-based approach to identify
such biomarkers across a spectrum of progression stages, including normal and tumor-
adjacent, premalignant, primary and late stage lesions. Bioinformatics data mining com-
bined with clinical validation of biomarkers by sensitive, quantitative reverse-transcription
PCR (qRT-PCR), followed by functional evaluation of candidate genes in disease-relevant
processes, such as cancer cell proliferation, motility and invasion. From 300 initial candi-
dates, eight genes were selected for validation by several layers of data mining and filtering.
For clinical validation, differential mRNA expression of selected genes was measured by
qRT-PCR in 197 clinical prostate tissue samples including normal prostate, compared
against histologically benign and cancerous tissues. Based on the qRT-PCR results, signifi-
cantly different mRNA expression was confirmed in normal prostate versus malignant PCa
samples (for all eight genes), but also in cancer-adjacent tissues, even in the absence of
detectable cancer cells, thus pointing to the possibility of pronounced field effects in prostate
lesions. For the validation of the functional properties of these genes, and to demonstrate
their putative relevance for disease-relevant processes, siRNA knock-down studies were
performed in both 2D and 3D organotypic cell culture models. Silencing of three genes
(DLX1, PLA2G7 and RHOU) in the prostate cancer cell lines PC3 and VCaP by siRNA
resulted in marked growth arrest and cytotoxicity, particularly in 3D organotypic cell culture
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conditions. In addition, silencing of PLA2G7, RHOU, ACSM1, LAMB1 and CACNA1D also
resulted in reduced tumor cell invasion in PC3 organoid cultures. For PLA2G7 and RHOU,
the effects of siRNA silencing on proliferation and cell-motility could also be confirmed in 2D
monolayer cultures. In conclusion, DLX1 and RHOU showed the strongest potential as use-
ful clinical biomarkers for PCa diagnosis, further validated by their functional roles in PCa
progression. These candidates may be useful for more reliable identification of relapses or
therapy failures prior to the recurrence local or distant metastases.
Introduction
Prostate cancer (PCa) remains a major public health problem in all western countries. PCa rep-
resents the most commonly diagnosed tumor entity after skin cancer in men, and is the second
most frequent cause of cancer-related death in the United States. In the US, 233,000 new cases
of PCa were diagnosed, and 29,480 men died of the disease in 2014 [1]. One in seven men may
develop invasive prostate cancer during their lifetime [1]. Measurements of serum prostate-
specific antigen (PSA) levels, followed by digital rectal examination (DRE) and histological
examination of prostate biopsies, are still the most widely used routine diagnostic methods for
PCa. In 1986, PSA was approved as a biomarker for monitoring and follow-up of PCa patients
by the US Food and Drug Administration [2]. Early studies have reported a significant decrease
in the mortality rate of PCa patients [3] after broad introduction of PSA tests for large-scale
population screening. However, more recent studies have revealed that PSA screening can lead
to widespread over-diagnosis and costly over-treatment of patients with indolent cancers [4].
As PSA is a tissue-specific, but not cancer-specific marker for the prostate, elevated levels of
PSA during and after chemotherapy or radical prostatectomy indicate failure of therapy, and
apparent recurrence of the disease. Although an incontestable clinical follow-up marker, PSA
levels only rise after PCa remission and when progression has already occurred. Accordingly,
PSA has little diagnostic and practically no predictive value for disease progression to locally
advanced cancer (< 10% of the patients), or even metastatic PCa. Recently however, a panel of
four kallikreins, in combination with PSA-aided risk stratification, was shown to be useful in
identifying men in their fifties with a highly increased risk for disease progression and develop-
ment of distant metastasis. This also provides a means to reduce the over-diagnosis of indolent
disease [5]. More sensitive, informative, disease- and cancer-specific biomarkers would be nec-
essary, in order to distinguish patients at high risk from those with indolent cancers or even
premalignant precursor lesions. This may also include markers that indicate cancer-associated
“field effects”, which were only recently described in prostate cancer [6] but have now become
a recurrent observation that is likely to become important for diagnostic purposes. Tissue-
based marker panels may have the potential to significantly improve diagnostics, resulting in
more precision and earlier detection, or they may indicate the frequently observed multifocal
nature of the disease [7]. Emerging applications of different ‘omics’ technologies such as geno-
mics, transcriptomics proteomics and metabolomics have promoted the field of biomarker
discovery significantly. Markers that are functionally involved in various stages of disease pro-
gression or metastatic spread might have the highest potential to successfully predict failures of
radiation and anti-hormone therapies, which lead to highly aggressive and metastatic, castra-
tion-resistant prostate cancer (CRPC). Such mechanistically involved markers may not only
significantly improve PCa management in clinical practice; they may also represent novel tar-
gets for therapeutic intervention. In clinical practice, the application of more predictive, tissue-
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based markers could be meaningfully combined with other high-risk parameters such as posi-
tive extracapsular or seminal vesicle invasion, advanced tumor stages (> T2c, T3 or T4), high
Gleason grades (> 8), or high to very high PSA level (> 20 ng/ml); and would be further sup-
ported by advanced imaging technologies such as MRI.
In recent years, molecular techniques such as microarray gene expression profiling and
next-generation sequencing (NGS) have greatly facilitated genome-wide studies of tumor gene
expression profiles. Accordingly, microarray and NGS-based gene expression profiling has
been widely used for identifying panels of prognostic [8] and predictive biomarkers, including
such that may be indicative for PCa recurrence [9,10], early and late stages of cancer progres-
sion, or field effects. Identification of novel, informative biomarkers for lung and colorectal
cancer by systematic mining of public gene expression datasets such as The Cancer Genome
Atlas (TCGA) has been reported [11,12] elsewhere. The TCGA database contains many large-
scale gene expression studies based on clinical PCa biopsies [13,14,15], derived from publicly
funded research and openly available datasets. The cBio Cancer Genomics Portal [16] (http://
www.cbioportal.org) is the main open-access resource for mining the TCGA cancer genomics
data sets, and currently hosts more than 21.000 tumor samples from> 20 different cancer enti-
ties and 91 studies. We have selected one of the largest and most comprehensive of these
microarray expression studies on PCa’s, performed mainly on clinical biopsies, conducted by
Taylor et al. at Memorial Sloan-Kettering Cancer Center (MSKCC) [13] in 2010. This study
includes 181 primary PCa samples, 37 metastatic PCa samples, 12 PCa cell lines and xeno-
grafts, and 29 normal prostate tissues as healthy controls. A large number of pathological and
clinical parameters such as Gleason grades, TNM stages, positive surgical margins, the status of
local invasion of cancer cells into lymph nodes, seminal vesicles, or extracapsular space, or dis-
tant metastasis are annotated. These parameters are deemed most important to assess PCa
aggressiveness, and reliably predict poor outcome of the disease. Our specific goal for data min-
ing was to utilize an open, unbiased approach, addressing a broad spectrum of normal tissues,
primary cancers, and late-stage, advanced lesions. Since the goal was not to predict the clinical
outcome or assess the individual risk for patients or patient subgroups based on mRNA expres-
sion data, the data were not split into training and test sets for cross-validation. We also did
not aim for the evaluation of a “predictive marker signature” to be used across other, indepen-
dent mRNA gene expression studies. Cross validation was therefore not essential in order to
confirm how statistically accurate a set of predictive biomarkers would perform in additional
data sets. In contrast, our aim was to identify previously unreported biomarkers and validate
them across the entire spectrum of clinical biopsies available from PCa. Our approach was
based on analysis of differential mRNA expression for the identification of biomarker candi-
dates, followed by their experimental correlation with the most critical clinical parameters in
independent sample collections, which were often of very different origin compared to the
microarray data. The main focus was on the functional validation of biomarkers in relation to
PCa initiation and progression, ideally combined with evaluating their potential diagnostic
value.
For independent validation of the initial findings, we mined additional resources, such as
the in silico transcriptomics (IST) database [17] (http://ist.medisapiens.com). This database
includes mRNA gene expression data from over 20.000 Affymetrix microarrays, covering 60
healthy tissues, 104 malignant and 64 other disease types. For data mining, we have utilized
Ingenuity Pathway Analysis (IPA), which provides gene association and ontology information,
and allows filtering of genes based on functional aspects. Last not least, we used the Pubmed
literature information system to filter out biomarkers that have been repeatedly described
before as associated with PCa. A batch mode text mining tool (http://pmid.us) was used, which
allowed sca1nning through the entire literature for the mesh heading “prostate cancer”, against
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co-occurrence of hundreds of candidate genes entered as “gene symbols”. With this strategy, a
set of 300 putative biomarker candidates was prioritized step by step, using a combination of
different data and text mining or filtering approaches, highlighting markers that were most
strongly correlated with general aspects of PCa progression, therapy failure, or progression to
metastatic CRPC, but not previously covered by a large body of scientific reports. Eight genes
were selected for clinical and functional validation. For this purpose, quantitative, internally
standardized real-time reverse-transcription PCR (RT-PCR) was applied, utilizing four inde-
pendent tissue sample collections from radical prostatectomy and cystoprostatectomy. These
contained normal cystoprostatectomy samples, histologically benign tissue from cystoprosta-
tectomy specimens with incidental prostate cancer, in addition to histologically benign tissues,
and malignant cancer from radical prostatectomy specimens.
Recent advances in cell biology have facilitated systematic functional validation studies
(functional genetics) of biomarker candidates, based on effective approaches such as small
interference RNA (siRNA or RNAi), CRISPR/Cas9 and TALEN technologies. Of these, siRNA
studies remain the most accessible, affordable and fastest technologies in experimental practice,
and represent the primary approach in functional target validation. In order to explore func-
tional effects of selected genes on growth, proliferation and invasive properties of prostate
cancer cells, siRNA knock-down studies for selected genes were performed in both 2D and
organotypic 3D models (organotypic cell cultures) using the poorly invasive VCaP and the
highly aggressive PC3 cell lines.
Materials and Methods
Analysis of gene expression profiling to identify candidate biomarkers
A panel of different bioinformatics analysis and filtering methods was applied to mine large-
scale gene expression profiling datasets, and to select the most informative, putative biomarkers
for prognosis and/or monitoring of disease progression (summarized in Fig 1). We used Bio-
conductor/R-based data normalization and the RMA (Robust Multi-chip Average) package for
processing and normalization of Affymetrix experiment sets extracted from the TCGA/cBio
portal. Next, genes were ranked according to differential gene expression across the main sam-
ple groups (N, normal; T, primary PCa; and M, metastatic PCa). For this purpose, we used sev-
eral statistical tests for significance (ANOVA, T-test or Z-score and the Mann-Whitney U
Test; and then filtered candidates by multiple testing corrections (Bonferroni). In parallel, we
used the SAM or “Significance Analyses for Microarrays” program, using False Discovery Rate
(FDR) criteria for gene selection. This approach resulted in overlapping, similar gene sets (data
not shown). We restricted our analysis to the large MSKCC dataset (218 tumor profiles, includ-
ing 37 metastases, 12 PCa cell lines, and 29 normal prostate tissues). Differential expression of
each gene across 181 primary cancer samples was compared to the 29 normal samples (T versus
N comparison). Similarly, expression in the 37 metastatic samples was compared to the 181 pri-
mary PCa samples (M versus T). The average fold change of mRNA expression and statistical
significance across all samples were calculated, and genes were ranked according to the stron-
gest differences in mRNA gene expression (fold change, see S1 and S2 Files). The top 300 hits
in each group (T vs. N, and M vs. T) were then subject to additional data filtering: Only those
genes were selected for follow up that showed the statistically most significant, robust and
reproducible differences between normal, primary PCa and metastatic PCa samples (based on
FDR estimations or Bonferroni-filter). We also used the Ingenuity Pathway Analysis (IPA)
software tool for additional filtering options of the original gene lists, based on both statistical
parameters as well as functional “gene ontology” and mechanistic pathway annotations. We
utilized the ranked list of candidates generated by IPA for additional correlation with clinical
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Fig 1. Schematic illustration of different bioinformatics analyses and filtering methods that applied to mine large-scale
gene expression profiling datasets and to select the most interesting biomarkers for subsequent clinical and functional
validation.
doi:10.1371/journal.pone.0155901.g001
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parameters (Kaplan-Meier plots), assessment of tissue-specific expression, and literature text
mining (next paragraphs). For cancer-specific genes identified as differentially expressed
between the N and T-groups, ranking was higher if differential mRNA gene expression was
also observed between the T and M subcategories.
For each selected gene, box-plot expression graphs were generated using an in-house html-
based data visualization tool (R-executable (REX)). This allows systematic, user-driven data
mining of datasets according to clinical parameters (e.g. tumor subgroups such as primary vs.
metastatic cancers, lymph node and extracapsular invasion, infiltration of surgical margins,
and distant metastasis). In addition, differential expression between low (4–6), intermediate
(7) and high (8–10) Gleason scores, or between different stages of the disease (> T2, T3 or T4),
and disease categories such as primary vs. lymph node metastasis, were systematically assessed
(Fig 2A). Next, we prioritized genes that were specifically, preferentially or strongly expressed
in prostate compared to all other human tissues, including other tumor entities. For this pur-
pose, tissue-specific expression scores provided by the IST online database were used (Fig 2C).
The tissue-specific expression scores and box-plot expression graphs for other selected genes
are summarized in S3 File.
Next, we addressed clinical outcome, but used other data sets in addition to the MSKCC
microarray data. For each selected gene, a Kaplan-Meier patient outcome plot based on an
independent, large-scale clinical study with publicly available data [15] was generated. For this
purpose, we focused on total survival and disease-free intervals, using non-parametric statistics
that discriminate patient survival functions from clinical lifetime data (Fig 2B). Since approxi-
mately 85–90% of patients even with locally advanced PCa show long-term survival (> 5 or 10
years) and mostly good clinical outcome, and only 10–15% of these patients progress to CRPC,
we have chosen equivalent numbers also for the Kaplan-Meier analyses. Accordingly, 85% of
the patients were grouped in the “low risk/good clinical outcome” category, compared to 15%
of high-risk patients that progress to advanced PCa.
Finally, to prioritize novel candidate biomarkers for subsequent functional and clinical vali-
dation, our list of biomarker candidates was filtered against the entire PubMed literature data-
base. Co-occurrence of candidate gene names and HUGO symbols with the term “prostate
cancer” in the PubMed database entries was screened systematically, using the Pubmed batch-
search tool (http://pmid.us). Genes that were mentioned more than five times in indexed scien-
tific publications were automatically excluded as “previously described in detail” (Status of lit-
erature search: September 2012). These last filtering steps led to eight genes for experimental
validation. Gene expression plots from IST database and dot plots from the MSKCC data set
are summarized in S3 File. We aimed to identify and confirm general PCa-specific biomarkers
(diagnostic markers), including biomarkers that may indicate early and multifocal disease
stages or “field effects”. In addition, we wanted to validate potential PCa progression markers
(prognostic markers) that might indicate the development of relapse, CRPC and metastatic
lesions after therapy failure.
Tissue samples for clinical biomarker validation
The Ethics Committee of the Hospital District of Southwest Finland approved the study proto-
col. It was in accordance with the Helsinki Declaration of 1975, as revised in 1996, with written
informed consent obtained from each participant. Two independent sets of prostate-related tis-
sue samples were used for clinical validation. The first set consisted of 180 prostate tissue sam-
ples obtained from a total of 90 primary PCa patients, operated by radical prostatectomy (RP)
in Turku University Hospital (TYKS). From 90 patients, only 2 patients had received HRH-
analogues before the surgery as preoperative treatment. From each prostate, two tissue samples
Novel PCa Biomarkers Based on the Combination of Bioinformatics, Functional and Clinical Validation
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Fig 2. Representation of the most important data format, plots and visualization results, used in data mining and prioritization of
candidate biomarkers, using the CACNA1D gene as an example. A) Dot plot chart illustrating the association of mRNA gene expression of
CACNA1D in normal and cancer samples with a panel of the most informative clinico-pathological parameters. B) Kaplan- Meier analyses,
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were taken. One was derived from the suspected cancerous area, the other from the adjacent
area, suspected to be benign. The histo-pathology of half of each tissue sample was examined
by TYKS pathologists, while the other half was immediately stored in guanidine isothiocyanate
(GITC) buffer for RNA extraction. Examination revealed that for 30 of the patients, both
samples were taken from the benign area; for 15 patients, both samples were taken from the
cancerous area; and for 45 patients, one sample was taken from benign and the other from the
cancerous area (as originally intended). Only two samples needed to be excluded because of
technical problems with RNA extraction. Finally, 178 samples (104 benign samples and 74
cancerous samples) were left for gene expression analysis by qRT-PCR. The clinical and patho-
logical features of all 90 PCa cases are presented in Table 1.
The second cohort included 19 prostate tissue samples, obtained from patients with bladder
cancer without any clinical symptoms of PCa. These were operated by cystoprostatectomy
(CP) at Skåne University Hospital in Malmö, Sweden. Experienced pathologists, using the
same protocol as previously described for the RP specimens, examined all prostate specimens.
12 of the 19 prostate specimens in this collection had incidental PCa (IPCa), while seven were
free of any detectable carcinoma foci. In the case of IPCa, tissue samples for gene expression
analysis were taken from the benign area.
Extraction and reverse transcription of RNA
Extraction of RNA from tissue samples has been previously described [18]. Briefly, the RNeasy
Mini Kit (Qiagen, Germany) was used according to manufacturer’s instructions. During RNA
extraction, and after the initial cell lysis step, a known amount of RNA of an artificially mutated
KLK3 gene, termed mmPSA, was added to the sample as an internal control and for absolute
quantification of expression levels. The quality of the mRNA obtained was verified by agarose
gel electrophoresis, and the final RNA concentration was measured by a NanoDrop N2000
showing the correlation of high levels of mRNA expression for CACNA1D with reduced overall survival analysis for PCa patients. C) Relative
expression of CACNA1D across a panel of 60+ normal and cancer-related human tissue types and diseases.
doi:10.1371/journal.pone.0155901.g002
Table 1. Characteristics of the patient cohort of 90 men with prostate carcinomawho underwent radi-
cal prostatectomy, PSA values were measured from serum preoperatively.
Median (min, max)
Number of patients: 90
Age at surgery (years): 62 (48, 72)
Preoperative serum PSA: 7.4 (2.7, 58)
Number of samples (percentage):
Pathological T stage/category
pT2 51 (57%)







* Values missing for four patients.
doi:10.1371/journal.pone.0155901.t001
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spectrophotometer (NanoDrop Technology, LTD Lab). Reverse transcribed cDNA was gener-
ated using the High Capacity cDNA Archive Kit (Applied Biosystems, USA), following the
manufacturer’s instructions.
Quantitative real-time RT-PCR
Our previously described protocol [19] for hydrolysis-enhanced luminescent chelate chemis-
try, based on time-resolved fluorometry, was used also here for quantitative real-time RT-PCR.
For each gene, a pair of specific primers, and matching reporter and quencher probes were
designed and purchased from Thermo Fisher (Germany) (S1 Table). To label the reporter
probes effectively with a nonadentate europium chelate, a previously described procedure [20]
was used. Real-time PCR was performed in a total volume of 25 μL, containing 2.5 μL of tem-
plate cDNA with Hotmaster™ Taq DNA polymerase (5 Prime, Germany) or AmpliTaq1 Gold
DNA polymerase (Applied Biosystems, USA). Samples were run in triplicates. To correct for
potential RNA degradation and the amount of RNA lost during extraction and reverse tran-
scription, the obtained transcript level data need to be normalized. Housekeeping genes (e.g.
GAPDH) are assumed to be transcribed at a constant level in different tissues and in all condi-
tions, and are widely used for normalization of RT-PCR results in relative quantification meth-
ods [21]. However, the reliability of housekeeping genes for normalization has often been
questioned due to their instability during storage and inconsistent expression changes in differ-
ent disease conditions [22,23]. Addition of a fixed amount of an artificial RNA, which is not
expressed in the specimens inherently as internal reference RNA to samples (before extraction)
is considered as more reliable alternative for normalization [24,25]. In this study, we have
taken the advantages of using artificial RNA (mmPSA) for normalization and the benefits of
using probes labeled with lanthanide chelates instead of Taqman probes, which enable the
time-resolved fluorometry for qRT-PCR assays.
Statistical analyses
For qRT-PCR analyses, the samples were considered positive if all three replicates were above
the lowest assay detection limit (LDL). The absolute, numeric quantity of gene expression
for any gene of interest was calculated by using internal standard values, normalized by the
amount of total RNA used in these assays. To test the differences of transcript levels of candi-
date genes between case and control samples as well as between different sample categories, the
non-parametric Mann-Whitney U test was applied. To evaluate the performance of each candi-
date gene in a diagnostic setting, a receiver-operating characteristic (ROC) curve analysis was
performed and the area under the curve (AUC) used to assess sensitivity and specificity of the
assays. To identify the association of mRNA transcript levels of a particular candidate gene
with tumor progression (measured as PSA relapse in the clinics), the RP samples were divided
in two groups, reflecting PSA relapse and No relapse, respectively; according to clinical follow-
up data. Any association between candidate gene expression levels and clinical or pathological
parameters such as Gleason grade, Gleason score, the percentage of cancer versus stromal
cells in tissue biopsies, and clinical T category (T-stage) was addressed by the non-parametric
Mann-Whitney U test, in order to identify statistically significant differences (p<0.05). Statisti-
cal analyses were performed with the SPSS software, version 22 (IBM, USA).
Functional gene knock-down studies with siRNAs
PC-3 androgen-independent human prostate cancer cells from bone-metastasized prostate
adenocarcinoma were purchased from ATCC (USA) [18] and grown in RPMI-1640 medium
at 37°C in standard cell culture conditions (95% humidity and 5% CO2). For siRNA knock-
Novel PCa Biomarkers Based on the Combination of Bioinformatics, Functional and Clinical Validation
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down studies, a total of 31 different siRNAs were ordered from Qiagen (Germany) (three dif-
ferent siRNAs for ACSM1 and four different siRNAs for each of the other seven genes). We
used several PCa cell lines, including PC-3, VCaP and LNCaP cells, for these functional valida-
tion experiments. To achieve the most efficient possible knock-down for each gene, several siR-
NAs were tested both individually as well as in pooled mixtures containing all three or four
siRNAs at equal concentrations. ALLStars Hs cell death control siRNA (Qiagen, Germany) was
used as a positive control to estimate the efficacy of transfection in each experiment. The siR-
NAs were pre-loaded into wells, Hiperfect transfection agent (Qiagen, Germany) in Opti-
MEMmedium (Invitrogen, USA) was added, and incubated for 15 minutes at room tempera-
ture. Finally, 2000 to 5000 PC-3, LNCaP or VCaP cells were added into each well. The final
concentrations of siRNA and Hiperfect in each reaction were 4 nM and 8 nM, respectively. To
evaluate the efficiency of RNA interference for each gene with the different siRNAs, total RNA
was extracted from transfected cells five days after siRNA transfection and specific mRNA
expression of the target genes was measured by qRT-PCR. To select those siRNA molecules
that result in the most effective knock-down, normalized expression values for each treated
sample were divided by the expression level of the candidate gene in untreated control cells
(“scrambled control”). To exclude any possible effects of this procedure on target gene expres-
sion, mock-transfected cells (using only transfection agent) were included as a second control.
Fluorescent assays to measure apoptosis and growth inhibition of VCaP
organoids after siRNA transfection
VCaP cells failed to grow in 3D conditions, if directly embedded into Matrigel or collagen cul-
tures. Therefore, VCaP cells were transfected with siRNAs as described for PC3. Next, trans-
fected VCaP cells were grown in round bottomed plates. The cells were allowed to aggregate
and form spheroids for seven days after transfection. A small number of spheroids (1–6) were
transferred into 3D culture plate wells. Such VCaP organoids showed few phenotypic effects,
but displayed altered organoid growth and different levels of apoptotic, dead or dying cells in
3D culture in response to siRNAs, thus were considered informative. Cell viability was deter-
mined with CellTiter-Glo assay according to the manufacturer’s instructions (Promega, USA).
Briefly, CellTiter-Glo buffer and lyophilized substrate was combined, 100 μl of said solution is
added to each sample well and the plate is shaken for 30 minutes. The luminescence which
results from cell lysis and which are in proportion with the amount of adenosine triphosphate
(ATP), was measured with an EnVision multilabel plate reader (Wallac, Finland). Further-
more, the NucView caspase 3/7 assay has been used which detects cells actively undergoing
programmed cell death (described in detail in [26,27,28].
2D cell migration and invasion assay
The invasive or migratory potential of the PCa cells was investigated with a “scratch wound” or
wound-healing assay, performed in 96-well ImageLock plates (Essen Bioscience, USA). Both
VCaP and LNCaP cells lacked invasive or motile properties in 2D or 3D conditions. These cell
lines did not show wound closure properties, and were not useful in scratch wound assays. For
this reason, we used PC3 cells, which also expressed seven of the eight candidate genes at signif-
icant levels, were straightforward to transfect by siRNAs, and also showed marked motile/inva-
sive properties in both 2D and 3D cell culture conditions. PC-3 cells were transfected with the
different individual siRNAs (as described above), and plated onto the wells after transfection.
When the cells reached confluence, which occurred roughly 72 hours after transfection (2–3
population doublings), a fixed-width wound was applied, using the Woundmaker device
(Essen Bioscience, USA). This approach provides uniform, standardized experimental settings
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across all wells of an entire 96-well multititer plate, and facilitates a reliable quantitative evalua-
tion of cell motility in each replicate. After wounding, wells containing a “scratched” mono-
layer were carefully washed once with PBS to remove floating, dislocated cells and cell debris.
Fresh cell culture medium was then added to the wells, and the closure of the wound bound-
aries was quantified and monitored for up to 72 h with the IncuCyte live-cell imager (Essen
Bioscience, USA). Images were acquired at 1h intervals, and analyzed using the automated Cell
Migration software module provided with the Essen IncuCyte imager. Kinetic, time-course
plots of wound closure were visualized in “micro-plate view” format, and multiple export met-
rics such as relative wound density, wound confluence and wound width were calculated as a
measure for cell migration, and to identify any quantitative changes to cell motility after siRNA
knock-down.
Organotypic 3D cell culture models and image acquisition for
morphological analyses
As described for the 2D wound healing experiments, we investigated the functional effects of
siRNA knock-down of candidate genes in a panel of PCa cell lines, and used LNCaP, VCaP
and PC3 cell lines for this purpose. LNCaP cells were difficult to transfect, did not express all
eight of the target genes, and failed to form overtly invasive structures in 3D culture. Further-
more, VCaP organoids did not readily grow when embedded into Matrigel, but had to be
grown in 3D round bottom culture plates, where few morphometric differences became appar-
ent. To monitor for changes in dynamic properties such as invasiveness or tumor-specific dif-
ferentiation patterns, we therefore focused mainly on PC3 cells. PC-3 cells are ideal for the
systematic analysis of morphologic, differentiation-related features and to evaluate the impact
of siRNA silencing on epithelial tumor cell plasticity. Embedded in Matrigel, PC-3 organoids
show a characteristic, disturbed differentiation capacity: initially, mature, acinar organoids
form that resemble low-grade, well-differentiated tumors and lack any invasive features. After
a spontaneous morphological conversion (during days 8–11 in 3D culture), PC3 organoids
form heavily invasive characteristic for advanced, metastatic CRPC tumors. Experimental
protocols for siRNA knock-down in 3D cell culture conditions were described elsewhere in
detail [29]. Briefly, PC-3 cells were transfected only with the most efficient, single siRNAs, as
described above. Transfection efficacy was evaluated three days after transfection by quantita-
tive qRT-PCR. 72 hours after transfection, cells were detached and transferred to uncoated
Angiogenesis slides (Ibidi GmbH, Germany), as described elsewhere [26,27,28]. Single, siRNA-
transfected cells were embedded between two layers of Matrigel (500–1000 cells/well), resulting
in an average cell density of approximately 1800 cells/cm2. Under these conditions, single PC3
cells typically give rise to a single, proliferating tumor organoid. Maintenance of siRNA knock-
down even> 10 days after transfer into 3D cultures was validated in a previous study [29].
After ten days in 3D culture, the resulting tumor organoids cells were stained using a live/dead
labeling strategy: Calcein AM live cell dye (ThermoFisher, USA) is actively incorporated and
accumulates in living cells, while and ethidium homodimer 1 (EthD-1) stains only dead and
apoptotic cells that lack intact plasma membranes. Stacks of confocal images were taken with
an Axiovert-200M microscope (Zeiss, Germany), using a Yokogawa spinning disc confocal
unit and a 5X Plan-Neofluar objective. A Z-stack of twenty focal images, with a step-size (dis-
tance) of 20–35 μm between layers, was acquired. SlideBook (Intelligent Imaging Innovations
Inc., USA) was used to capture composite images and to create intensity projections. Next, the
ImageJ software (NIH, USA) was used for initial image normalization and to remove back-
ground and noise. The Automated Morphometric Image Data Analysis software package
(AMIDA, University of Turku) was used for analysis of images and quantitative measurements
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of morphological changes in three-dimensional tumor organoids formed by PC-3 cells. The
AMIDA software is publicly available, and basic operations and concepts have been previously
described [28].
Morphometric and phenotypic parameters for 3D image analyses
Strong cell-cell interactions between tumor cells lead to mature organoids, often surrounded
by a basement membrane (BM) or basal lamina. Such organoids are also formed by PC3 cells,
and recapitulate key parts of the epithelial differentiation program of normal and low-grade
PCa cells. Mature organoids are typically round, smooth and lack invasive processes. In con-
trast, advanced and aggressive PCa cells form irregular, rough and rapidly growing organoids,
devoid of a functional BM; and may show pronounced invasive features. According to these
different morphologies, a total of 26 different parameters were evaluated, focusing mainly on
3D organoid growth, differentiation/maturation, and invasive properties. The Area parameter
of segmented organoids (measured as number of pixels) is a simple measure of cell growth and
proliferation, and correlates with the number of cells within organoids. Cytotoxic effects typi-
cally result in reduced Areameasures; they often also lead to increasedDensity and less inva-
sive structures (increased Roundness).
The AppIndex,MaxApp and Roughness functions are measures for invasive processes
observed in 3D cultures. Silencing of genes can affects invasive properties, and alter the number
and degree ofMaxApp values (# of invasive protrusions/organoid), often without affecting
proliferation (Area function). Invasive properties are negatively correlated to the Roundness
measure, which represents a measure for epithelial differentiation, maturation, formation of a
functional BM and strong cell-cell contacts. Furthermore, theDensity function positively cor-
relates with well-differentiated 3D structures, but negatively with invasiveness. In practice,
effects resulting in growth inhibition often coincide or overlap with anti-invasive effects, and
both can co-occur frequently.
Results
Analysis of differential mRNA gene expression profiles and identification
of putative marker genes
Eight genes (ACSM1, TDRD1, PLA2G7, SPON2, DLX1, CACNA1D, RHOU, and LMNB1) were
selected by bioinformatics data mining, based on their overexpression in primary PCa com-
pared to normal tissue samples mainly in the MSKCC data set; and expression was confirmed
in other data sets such as the IST database. Three of the candidates (CACNA1D, RHOU,
and LMNB1) showed potency to discriminate metastatic PCa from primary PCa. One gene
(PLA2G7) has been previously identified by our laboratory as a putative diagnostic marker for
PCa progression, in connection with the TMPRSS2-ERG fusion gene status. PLA2G7 was sug-
gested as a functionally important drug target, in particular in ERG-positive PCa [30,31]. In
this study, PLA2G7 was included as a reference gene for both internal validation purposes and
optimization of functional assay development. The genomic location and physiologic function
of the candidate biomarkers are listed in Table 2.
Clinical validation of differential gene expression for selected candidate
genes by quantitative real-time RT-PCR
To investigate the upregulation of the selected eight candidate biomarker genes in cancer, the
mRNA expression of the eight genes was measured by quantitative real-time RT-PCR. To iden-
tify genes that could discriminate between different histological tumor subtypes, all tissue
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samples analyzed were assigned into four sample groups: 1. cystoprostatectomy (CP) samples
with no cancer foci (CP-B), 2. cystoprostatectomy samples with incidental PCa (CP-IPCa), 3.
histologically benign radical prostatectomy samples (RP-B) and 4. malignant radical prostatec-
tomy samples (RP-PCa). Expression of ACSM1, CACNA1D, PLA2G7 and SPON2 was detected
in all tissue samples across different groups of samples. However, the expression of DLX1 was
detected in 73/74 (99%) of the RP-PCa samples, but could not be detected in any of the seven
CP-B samples. Detection of genes in various sample groups is outlined in Table 3. The levels of
differential expression between each set of two sample groups and across different clinic-patho-
logical parameters were analyzed by the non-parametric Mann-Whitney U test (Table 4).




ACSM1 (Acyl-CoA Synthetase Medium-Chain
Family Member 1)
16p12.3 GTP binding and fatty acid ligase activity. Related pathways: Metabolism and fatty
acid beta-oxidation
CACNA1D (Calcium Channel, Voltage-
Dependent, L Type, Alpha 1D Subunit)
3p21.1 Involved in muscle contraction, hormone or neurotransmitter release, and gene
expression. Related pathways: MAPK signaling pathway and Developmental Biology
DLX1 (Distal-Less Homeobox 1) 2q31.1 Function as a transcriptional regulator of signals from multiple TGF-{beta} superfamily
members. Related pathways: Regulation of nuclear SMAD2/3 signaling and
Packaging Of Telomere Ends
LMNB1 (Lamin B1) 5q23.2 Involved in nuclear stability, chromatin structure and gene expression. Related
pathways: Cell Cycle, Mitotic and Cytoskeletal Signaling
PLA2G7 (Phospholipase A2, Group VII) 6p12.3 Hydrolyze phospholipids into fatty acids and other lipophilic molecules. Related
pathways: Apoptotic Pathways in Synovial Fibroblasts and Activation of
cAMP-Dependent PKA
RHOU (Ras Homolog Family Member U) 1q42.13 Regulation of cell morphology, cytoskeletal organization, and cell proliferation. Related
pathways: Signaling by GPCR and Signaling by Rho GTPases
SPON2 (Spondin 2, Extracellular Matrix
Protein)
4p16.3 Cell adhesion protein that promotes adhesion and outgrowth of hippocampal
embryonic neurons. Related pathways are Phospholipase-C Pathway and ERK
Signaling
TDRD1 (Tudor Domain Containing 1) 10q25.3 Plays a central role during spermatogenesis by participating in the repression
transposable elements and preventing their mobilization. Related pathways: Gene
Expression and Mitotic Prophase
* Based on genomic locations by Ensembl (http://www.ensembl.org)
+ Based on GeneCards Human Gene Database (http://www.genecards.org).
doi:10.1371/journal.pone.0155901.t002
Table 3. Frequency of detection of target mRNAs in benign prostate tissue from patients without PCa (CP-B samples) and with incidental PCa
(CP-IPCa samples) and in histologically benign (RP-B samples) and cancerous (RP-PCa) tissue of patients with PCa.
Number and percentage of samples in which target mRNA could be detected
Target mRNA CP-B samples (n = 7) CP-IPCa samples (n = 12) RP-B samples (n = 104) RP-PCa samples (n = 74)
LMNB1 5 (71%) 12 (100%) 104 (100%) 74 (100%)
ACSM1 7 (100%) 12 (100%) 104 (100%) 74 (100%)
CACNA1D 7 (100%) 12 (100%) 104 (100%) 74 (100%)
RHOU 2 (28%) 7 (58%) 104 (100%) 74 (100%)
DLX1 0 (0%) 5 (41%) 88 (85%) 73 (99%)
TDRD1 2 (28%) 6 (50%) 101 (97%) 72 (97%)
PLA2G7 7 (100%) 12 (100%) 104 (100%) 74 (100%)
SPON2 7 (100%) 12 (100%) 104 (100%) 74 (100%)
doi:10.1371/journal.pone.0155901.t003
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The comparison of the cancer-related sample group 4 (RP-PCa) vs. the validated benign
sample group 1 (CP-B), and between all cystoprostatectomy samples (CP) versus all radical
prostatectomy (RP) samples revealed statistically significant expression differences for all eight
genes. Corresponding to the initial gene identification and ranking strategy, it is not surprising
that the validated normal samples (CP-B) showed marked differences to all three, directly or
indirectly disease-associated sample groups, even if these did not contain overt malignant tis-
sue. In particular, the comparison of the confirmed benign cystoprostatectomy sample group 1
(CP-B) to the radical prostatectomy sample group 3 (RP-B) resulted in highly statistically sig-
nificant upregulation for all eight genes, despite the fact that these biopsies did not contain his-
tologically detectable prostate cancer. This finding points to the generalized observation that
many malignancy-related marker genes may be upregulated and be detectable already in non-
malignant areas, adjacent to malignant tissue. While such “field effects” have been described in
head & neck or lung cancers already since the 1950, the corresponding concept in PrCa has
only been recently emerging. The same basic observations apply for the comparisons of the
CP-B group against the malignant samples (RP-PCa) or all radical prostatectomy samples
combined (RP). As would be expected, this latter group showed higher expression patterns for
most genes than cystoprostatectomy samples with small, incidental cancer.
When the two large groups of RP samples (benign RP-B and malignant RP-PCa) were
compared with each other, most of the differences were statistically still highly significant
(p0.001), except for RHOU, LMNB1 and PLA2G7, indicating the stronger impact of detect-
able cancer tissue on biomarker expression patterns compared to likely field effects. Similarly,
the comparison of histologically benign radical prostatectomy samples to incidental samples
from cancerous patients (RP-B vs. CP-IPCa) revealed statistically significant differential
expression (p 0.05) for six of the eight genes, with the exception of TDRD1 and DLX1. Also
these observations may be due to the aforementioned field effects in cancer-associated or adja-
cent tissues. In contrast, and probably due to the small sample size, no statistically significant
differences for any of the eight genes were observed between the CP-B and CP-IPCa sample
groups. Experimental results and fold-changes for all eight biomarker genes across sample
groups on a logarithmic scale, in relation to KLK3 (PSA), are shown in Fig 3.
Table 4. Association of mRNA expression of selected target genes in prostate tissues, and statistical correlation with major clinical and pathologi-
cal parameters of PCa biopsies, calculated with the Mann-Whitney test.
Target mRNA
KLK3 RHOU ACSM1 CACNA1D LMNB1 TDRD1 PLA2G7 DLX1 SPON2
CP (n = 19) vs. RP (n = 178) 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CP (n = 19) vs. RP-PCa (n = 74) 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CP (n = 19) vs. RP-B (n = 104) 0.008 <0.001 <0.001 <0.001 0.001 0.001 <0.001 0.008 <0.001
RP-B (n = 104) vs. CP-IPCa (n = 12) 0,22 0.05 <0.001 0.007 0.02 0.11 <0.001 0.53 0.003
CP-IPCa (n = 12) vs. CP-B (n = 7) 0.34 0.15 0.31 0.31 0.12 0.15 0.8 0.056 0.310
RP-PCa (n = 74) vs. RP-B (n = 104) 0.9 0.30 0.001 0.001 0.14 <0.001 0.804 <0.001 0.00
PCa Gleason  7 (n = 43) vs. Gleason ,6 (n = 43)* 0.866 0.249 0.849 0.799 0.331 0.115 0.048 0.074 0.707
pT 2 (n = 51) vs. pT 3,4 (n = 35)* 0.161 0.535 0.833 0.004 0.072 0.377 0.715 0.001 0.775
PSA relapse (n = 15) vs. No PSA relapse (n = 65) * 0.225 0.980 0.206 0.090 0.151 0.209 0.427 0.156 0.023
* For patients represented by two samples, a single value of mRNA expression of each gene for each patient was chosen, consistently from the right lobe
of the prostate. Statistically signiﬁcant P values are shown in red color. CP represents cystoprostatectomy samples, RP-B represents the histologically
benign radical prostatectomy samples and RP-PCa represents the cancerous radical prostatectomy samples. Gleason indicates the Gleason score of
entire prostate specimen removed from the patient.
doi:10.1371/journal.pone.0155901.t004
Novel PCa Biomarkers Based on the Combination of Bioinformatics, Functional and Clinical Validation
PLOS ONE | DOI:10.1371/journal.pone.0155901 May 19, 2016 14 / 30
Association of mRNA expression of the candidate biomarker genes with
clinical and pathological parameters
The clinical cancer samples were divided into additional sample groups, based on Gleason
scores (ranging from Gleason 4–9). No statistically significant differences for mRNA expres-
sion were observed between different single Gleason scores, probably because none of the sam-
ple groups were large enough. Thus, clinical samples were divided in two larger groups: one
consisting of more aggressive (Gleason grades7–9) tumors, the second of less aggressive
(Gleason< 7; including Gleason 4, 5, and 6) tumors. For the patients represented by two sam-
ples, a single value of mRNA expression of each gene for each patient was chosen, consistently
from the right lobe of the prostate. Applying the single value of mRNA expression of each gene
for each patient resulted in significant differences for only PLA2G7 (p = 0.048).
When using a single value of mRNA expression of each gene, and for each patient repre-
sented by two samples (consistently from the right lobe), differential expression of CACNA1D
and DLX1 correlated strongly with the T2 and T3 categories of TNM staging (p = 0.004 and
0.001, respectively). Next, we examined if differential mRNA expression of any of the eight
genes might predict cancer recurrence or progression, and would therefore harbor specific
prognostic potential. Applying the single mRNA expression value for each patient resulted in a
significant difference only for the expression of SPON2 (p = 0.023) between patients with or
without PSA relapse.
Fig 3. Differential mRNA expression levels for eight candidate biomarker genes and KLK3 (mRNA copy number/μg total RNA) in
cystoprostatectomy samples (CP), histologically benign radical prostatectomy samples (RP-Be) and cancerous radical
prostatectomy samples (RP-PCa). Boxes show the interquartile range with the line in the middle of them denoting the median value and
circles represent the outliers.
doi:10.1371/journal.pone.0155901.g003
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Next, cancer samples from radical prostatectomies (RP-PCa) were also divided into two
groups according to the content of stromal tissue within the biopsies. One group comprised all
samples containing over 33% of tumor content (and< 66% stroma), the other those below
33% of carcinoma content (> 66% stroma). The expression of DLX1 was significantly different
between two groups and correlated with high tumor content, with p- values of 0.018.
Specificity and sensitivity of biomarkers—receiver operating curves
(ROC)
To assess the sensitivity and specificity of the candidate biomarkers, ROC analysis was used
and the area under the curve (AUC) measured for each prospective biomarker (Table 5 and Fig
4). RP-PCa samples were considered as positive samples by definition. Even when utilizing
only one of the two available samples for each patient, and comparing these samples against all
CP samples (defined as negative by default), particularly high sensitivity and specificity was
observed for all eight biomarkers. The AUCs calculated varied between 0.74 and 0.93, indicat-
ing 93% specificity in the best cases (Table 5). To examine the importance of the cancer field
effect and to implement the predictive power of these genes for very early stages of PCa pro-
gression, all RP-B samples were considered by default as positive for cancer (one sample for
each patient for which two benign samples were available). When comparing histologically
benign samples from cancer patients against all CP samples, which were defined as negative,
particularly high AUC values (varying between 0.69 and 0.92) were observed for all of the eight
genes.
Functional gene knock-down studies by siRNA transfection
Systematic knock-down of all eight marker genes could be successfully performed in VCaP and
PC3 cells. SiRNA transfection in LNCaP cells turned out to be highly variable and inconsistent,
and not included here. For all cell lines, we used Hiperfect as the most effective transfection
reagent, showing consistently very low cytotoxicity, and allowing comparably high concentra-
tions of siRNAs to be used. When testing the knock-down efficacy of different specific siRNAs
for different gene, qRT-PCR measurements revealed maximum knock-down levels between
69% to 95% in PC-3 and VCaP cells (Table 6). For seven of the eight genes, a single siRNA was
shown to be most effective transfection and superior to pooled siRNA. Transfection of VCaP
cells by siRNAs was more difficult compared to PC3, but could be increased after further opti-
mization of the standard transfection protocol.
Table 5. AUCs (Area under the Curve) calculated for each of the eight biomarkers and KLK3 for com-
parison. The table presents the AUC values for each gene in the ROC analyses.
Target
mRNA
RP-PCa (only one sample per patient
n = 59) Vs. CP (n = 19)
RP-Be (only one sample per patient
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Knock-down of candidate genes in VCaP organoid cultures
Since VCaP cells did not show striking morphometric changes after siRNA knock-down in
either 2D or 3D conditions, we measured the effect of siRNAs on organoid growth and prolif-
eration in round bottom plates indirectly, using the CellTiter-Glo assay. These results are sum-
marized in Table 7: Organoid proliferation as measured by the CellTiter-Glo assay was affected
significantly only by knock-down of DLX1, PLA2G7, and RHOU; the strongest effects were
seen with AllStar control siRNAs. In addition, the impact of siRNA silencing on apoptosis in
VCaP organoids was assessed by the NucView caspase 3/7 assay. Furthermore, the number of
dead and dying cells inside VCaP organoids was measured by incorporation of ethidium
homodimer, and numbers were quantified by image analyses. The results for VCaP organoids
in 3D culture are summarized in Table 8. The most prominent effects on cell death in VCaP
Fig 4. ROC analyses for KLK3mRNA levels and expression levels of 8 target mRNAs in cases classified as positive or negative for PCa. To
simplify the analysis, patients with two cancerous/benign samples were represented by a single value of mRNA expression of each gene. A. RP-PCa
samples were considered as positive samples and compared against all CP samples (defined as negative). High sensitivity and specificity was
observed for all eight biomarkers. B. RP-Be samples were considered as positive samples and compared against all CP samples (defined as negative).
doi:10.1371/journal.pone.0155901.g004
Table 6. Knock-down efficacy as confirmed by qRT-PCR after transfection of PC3 cells with corre-
sponding siRNAs.







SPON2 not expressed in PC3 cell line
TDRD1 88%
doi:10.1371/journal.pone.0155901.t006
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organoid are exerted by knock-down of RHOU and CACNA1D. Knock-down of DLX1 and
TDRD1 also result in measurable, but smaller induction of apoptosis and cell death.
Knock-down of RHOU and PLA2G7 decreases the invasion and motility
of PC-3 cells
The effect of silencing the expression of different genes on cell migration and motility was eval-
uated by wound healing experiments. Under 2D cell culture conditions, the comparison of
cells transfected with scrambled siRNA or untreated (mock transfected) cells revealed only
slight difference in cell motility and migration for seven of the eight genes under investigation.
However, PC-3 cells with knock-down of RHOU expression showed strong, reproducible com-
bined effects on both proliferation and cell motility or migration (Fig 5), in comparison with
untreated cells and those transfected with scrambled control siRNAs (Fig 6). In addition,
silencing of PLA2G7 resulted in only small, but reproducible effects on cell motility. VCaP cells
lack invasive properties and were not used in these assays.
Effects of gene silencing on multicellular 3D morphology and tumor
growth
Functional validation and siRNA knock-down experiments were also performed in 3D organo-
typic culture, focusing on PC3 cells because VCaP organoids had to be grown in non-adherent
suspension cultures and did not show prominent morphometric differences after siRNA silenc-
ing. With PC3 cells however, organoids readily formed in 3D culture conditions, and we tested
morphometric changes in organoid growth and architecture, combined with assessing the
growth rate cell death in 3D culture conditions. Results of siRNA knock-down in PC3 orga-
noids, grown in 3D organotypic culture, were significantly more prominent and easier to
quantitatively measure, compared to PC3. For this reason, we have focused mainly on PC3
organoids.
Table 7. Growth inhibition of VCaP cells by siRNA knock-down in 2D culture, as measured by the CellTiterGlo assay (2000 cells/well; 384-well
microtiter plate).
Untreated PLA2G7 DLX1 RHOU CACNA1D TDRD1 LMNB1 SPON2 ACSM1 ALLstar
100.0% 79.2% 82.4% 91.0% 103.6% 102.3% 107.3% 95.7% 102.1% 53.1%
doi:10.1371/journal.pone.0155901.t007
Table 8. Impact of gene silencing on spheroid size, relative degree of apoptosis, and number of dead cells in VCaP spheroids.
Sample Apoptosis mean Apoptosis total signal EthD mean EthD total signal Spheroid area total sum in wells
UNTREATED 100% 100% 100% 100% 100%
SCRAMBLED 99% 88% 111% 95% 89%
DLX1 101% 102% 136% 136% 100%
RHOU 108% 146% 248% 322% 134%
SPON2 122% 107% 120% 103% 87%
TDRD1 133% 99% 220% 158% 78%
LMNB1 114% 153% 184% 243% 133%
CACNA1D 115% 142% 187% 233% 125%
PLA2G7 115% 102% 106% 92% 89%
ACSM1 108% 102% 117% 117% 98%
ALLSTAR 124% 94% 356% 264% 75%
doi:10.1371/journal.pone.0155901.t008
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Knock-down of DLX1 in PC3 cells resulted in the most significant, phenotypic effects upon
gene silencing. In comparison to untreated PC3 cells (Fig 7A), RNAi for DLX1 causes charac-
teristic stunted organoid growth, and resulted in small organoids with high cell density (Fig
7B). This coincides with a complete block of invasive properties. Interestingly, the number of
apoptotic cells (red spots in Fig 7A and 7B) is not significantly increased, indicating that loss of
DLX1 functions does not trigger programmed cell death, but may primarily affect cell cycle
progression instead.
In comparison, knock-down of the RHOU (Fig 7C) and CACNA1D genes (Fig 7D) resulted
in larger, less strongly growth-inhibited organoids compared to DLX1, which were significantly
smaller than those observed in scrambled siRNA controls. Also RHOU and CACNA1D silenc-
ing effectively inhibited invasive properties observed in untreated PC3 cultures, however with
smaller, less significant cytotoxic and growth-inhibitory effects. Silencing of the genes PLA2G7
(Fig 8B) and LAMB1 (Fig 8C) resulted in a similar, more or less specific blocking of the invasive
properties of PC-3 organoids observed in an organotypic 3D microenvironment. Also here,
silencing of PLA2G7may be more cytotoxic compared to LAMB1, indicated by smaller and
denser organoid structures. In contrast, silencing of the TDRD1 gene (Fig 8D) resulted in
opposing effects, leading to more prominent invasive features and generally larger organoids,
compared to untreated controls.
The impact of siRNA gene silencing on growth and invasive properties in 3D cultures could
also be quantitatively analyzed, based on the AMIDA automated image analysis software that
Fig 5. Wound healing assay with PC-3 cells following a 72-hour siRNA transfection. The wound healing results of
PC-3 cells treated with RHOU and scrambled siRNA vs. untreated PC-3 cells (mock transfection). Representative images
taken 50 h after scratching/wound healing.
doi:10.1371/journal.pone.0155901.g005
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Fig 6. Wound healing curves of untreated (scrambled controls) and specific gene silencing experiments by siRNA, transfected
into PC-3 cells. A. Wound healing curves of untreated PC-3 cells and PC-3 cells after siRNA mediated knock-down of all eight
candidate genes. AllStar control siRNA induces programmed cell death and was used here as a control for efficacy of siRNA
transfection. B. Wound healing/cell migration for RHOU-silenced PC-3 cells, compared to scrambled control.
doi:10.1371/journal.pone.0155901.g006
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measures various morphometric features. These results are summarized in Fig 9. Knock-down
of DLX1 is the only treatment that results in a very significant reduction of organoid size
(Area). As described above, this is characteristically concomitant with increased density (Den-
sityG) and a reduced average number of cells inside the organoids (CellNumberG; all shown
on left panel of Fig 9).
In contrast, siRNA-mediated silencing or knock-down of the genes RHOU, PLA2G7,
CACNA1D and LAMB1 does not result in smaller organoid size (Area and CellNumberG
unchanged or even slightly increased), although their structural density can be increased (Den-
sityG). Nevertheless, silencing of both RHOU and PLA2G7 cause a very significant reduction of
Fig 7. Representative confocal images 3D organoids, formed by PC3 cells embedded in Matrigel. A. Control cells were treated with non-
functional scrambled siRNA; or with only transfection agent alone. These organoids showmultiple invasive processes, typically involving chains of
cells (collective invasion pattern).B. Silencing of DLX1 results in prominent growth inhibition and formation of small, round, dense and poorly
proliferative organoids, but do not show any invasive properties. C. Similarly, silencing of the RHOU gene andD. of the CACNA1D calcium channel
result in round organoids devoid of any invasive processes.
doi:10.1371/journal.pone.0155901.g007
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macroscopic invasive features (reduced MaxApp and Roughness measures), combined with
strongly increased Roundness.
The situation for LAMB1 and CACNA1D silencing are less obvious and clear. Nevertheless,
also here the Roughness measure (indicating small, single-cell or subcellular structures invad-
ing from the organoid into the microenvironment) is significantly reduced; which coincides
with increased Roundness (indicating a more pronounced maturation or differentiation of the
organoids).
Silencing of TDRD1 results in observations that are largely opposing to interfering with any
of the other seven candidate genes. TDRD1 knock-down causes the PC3 organoids to signifi-
cantly increase in size (Area +), but these simultaneously are less dense (DensityG) although
Fig 8. Images of 3D organotypic cell cultures of PC3 cells, embed in Matrigel, after segmentation and subsequent image analysis using the
AMIDA software package. A. Untreated cells form large organoids with overt invasive processes. B. Silencing of PLA2G7 and C. laminin beta 1
(LMNB1) result in well-rounded, poorly invasive organoids, with higher cell density. D. In contrast, silencing of the TDRD1 gene results in significant
induction of invasive properties, further loss of the structural organization or maturation of organoids, and decreased cell density.
doi:10.1371/journal.pone.0155901.g008
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they contain more cells (CellNumberG) and also show many more invasive structures (Max-
App), and are slightly less rounded (Roundness). This indicates that TDRD1 gene functions
may be related to regulation of cell-cell interactions, maturation, differentiation, and integrity
of three-dimensional tissue-like structures.
Fig 9. Quantitative assessment of phenotypic changes as the result of siRNA silencing in organotypic 3D cultures.
doi:10.1371/journal.pone.0155901.g009
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Discussion
Although serum PSA is widely used as a good indicator for early detection of PCa and tumor
load, but has only poor prognostic value in clinical practice, and does not support timely ther-
apy management and intervention. Increase of serum PSA levels is typically delayed and does
not increase with the onset of therapy failures and recurrence of tumors. PSA is therefore not
predictive for the development of metastatic CRPC. New biomarker candidates are needed that
allow a more timely management of the disease, and may ideally predict emerging relapses or
therapy failures prior to the recurrence of large tumor masses, such as local lymph node or dis-
tant bone metastases. Due to the pronounced heterogeneity and complex nature of CRPC, it
would be most beneficial if existing panels of biomarkers, including PSA and maybe other kalli-
kreins, could be combined with additional, novel biomarkers that are more specific for PCa
and the mechanisms of disease progression. In practice, this relates to the identification of bio-
markers or marker panels that could clearly distinguish indolent from aggressive cancers; or in
contrast indicate early stages of progression including field effects and multifocal cancer initia-
tion [7]. Ideally, these markers may also be functionally correlated with and involved in the
progression to CRPC. Such earlier detection of therapy failures would allow more timely adap-
tations to personalized therapy regimens, more individualized and flexible therapeutic deci-
sions, thus saving lives and prolonging patient survival. Most importantly for National
healthcare systems, these might also reduce persistent management problems that relate to the
frequent over-detection and overtreatment of PCa. A considerable number of studies used
gene expression profiles to identify novel diagnostic and predictive biomarkers, or defined
multi-gene signatures that may correlate with certain clinical and pathological parameters
[32,33]. However, only few predictive markers identified in silico have also been validated
simultaneously for clinical and functional or mechanistic relevance. For this purpose, we com-
bined i) a genome-wide bioinformatics data mining approach with ii) direct, clinical biomarker
validation (using sensitive quantitative RT-PCR), followed by iii) functional evaluation of these
candidate genes in disease-relevant processes, such as cancer cell proliferation, motility and
invasion.
Gene selection and prioritization: Prioritization of candidate genes was performed based on
a spectrum of clinical parameters, all intended to simultaneously increase the clinical and func-
tional relevance of these genes simultaneously. These were as follows: i) high or predominant
mRNA expression in prostate tissues, and statistically significant correlation with ii) clinical
parameters such as Gleason grades, ii) tumor stage, iii) local or distant tumor invasion; iv)
lymph node and extracapsular invasion, v) progression to CRPC and metastasis; vi) failure to
respond to anti-androgens and vii) association with poor patient survival. Four of the eight
genes had not been previously associated with PCa diagnosis or disease progression (ACSM1,
RHOU, LMNB1, and DLX1). Our data indicate that CACNA1D, DLX1 and SPON2might be
most informative for prognostic applications, providing the highest predictive value for clinical
decision-making. Independent of our studies, SPON2 was only recently reported [34,35] as a
novel marker for blood and serum based biomarker detection of CRPC. In addition, three
genes (CACNA1D, TDRD1, and PLA2G7) had been previously reported as potential ERG-tar-
get genes [36,37,38,39], specifically induced by expression of the TMPRSS2-ERG fusion tran-
script found in 40–70% of PCas. In addition, Shaikhibrahim and colleagues reported the
overexpression of TDRD1 as an epigenetics-related gene in poorly and moderately differenti-
ated prostate tumors, compared to normal glands [40]. Overexpression of PLA2G7 as a mem-
ber of arachidonic acid and prostaglandin pathway in PCa, specifically in ERG positive cancers,
has been reported [30,41]. Moreover, a specific association of PLA2G7 with aggressive forms
of PCa, it’s prognostic potential as a biomarker, as well as a novel drug target were suggested
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[31,42]. Furthermore, PLA2G7 was selected in this study as a positive control gene for our
functional evaluation, based on earlier validation studies [43].
Clinical Validation: We used quantitative RT-PCR technologies to validate differential
expression between normal prostate, benign tissues, and malignant cancers. For seven of the
eight candidate genes (all except PLA2G7), no predictive association with progression to meta-
static CRPC had been previously reported. Only very recently, two of the studied genes (DLX1
and TDRD1, in combination withHOXC6) were independently validated as components of a
novel prognostic gene signature [44], based on urine sediment diagnostics. Our data confirm
these exciting new findings, and validate their relevance as biomarkers. Our study is also rele-
vant as independent evidence for these studies, since they are based on different experimental
methods (qRT-PCR), patient cohorts and primary biopsy materials (cystoprostatectomy and
radical prostatectomy). All of our eight candidate genes showed statistically significantly differ-
ent expression between normal/benign prostate and malignant PCa sample groups, low versus
high Gleason grade tumors (PLA2G7), PSA relapse versus no relapse (SPON2), and low versus
high TNM stages (CACNA1D and DLX1). The relevance of all putative prognostic markers
was further confirmed by the ROC analyses, indicating generally high AUC values. In all cases,
these exceeded the informative, prognostic value of PSA (AUC = 0.740). The highest AUC val-
ues were observed for PLA2G7 (0.935) and ACSM1 (0.921), followed by SPON2 (0.863), CAC-
NA1D (0.839), TDRD1 (0.830), LMNB1 (0.789), DLX1 (0.783) and RHOU (0.773). In addition,
all eight genes are differentially expressed between validated normal prostate biopsies. One of
the most consistent and striking observations in our study was that for all eight marker genes
analyzed here, cancer-adjacent samples show indication of significant field effects, even if they
do not contain any detectable cancer tissue. Comparable AUC values for RP-Be vs. CP samples
with RP-PCa vs. CP indicates that even in the histologically benign areas, changes in gene
expression closely associated with the presence of prostate cancer, could be detected. The prev-
alence of field effects in PCa is currently only emerging, but may become very important and
informative for diagnostic purposes in the near future. Currently, there are very few mechanis-
tic studies that could explain the molecular nature and origin of these field effects in detail.
Functional Validation: For the experimental evaluation of gene functions, we utilized orga-
notypic, 3D model systems that recapitulate key aspects of PCa biology, including local inva-
sion into the extracellular matrix (ECM), and specifically investigated the possible involvement
of these candidate genes in cell motility, another hallmark of aggressive PCa cells, studied by
wound healing assays. Functional validation was performed in both VCaP and PC3 cells. How-
ever, technical difficulties such as low siRNA transfection efficacy and the lack of cancer-asso-
ciated, invasive or motile properties in 2D and 3D growth conditions in VCaP cells have
prompted us to focus mainly on the PC3 cell line. Despite their aggressive potential, PC3 cells
retain the capacity to differentiate into functional acini-like structures, in particular when
embedded in laminin-rich ECM. Such acini spontaneously transform into overtly invasive
structures, thus recapitulating the dynamic progression to metastatic CRPC. Although PC-3
cells do not recapitulate all aspects of PCa biology equally well (e.g. due to the lack of androgen
receptor expression), they were considered most suitable for our specific functional validation
purposes. The most relevant aspects were related to the dynamic invasive potential, pro-
nounced tumor cell plasticity, and ease of siRNA transfection. Significant levels of mRNA
expression for seven of the eight candidate genes (except SPON2) were detected in PC-3, and
all eight were expressed in VCaP cells. Expression of all genes could be effectively reduced by
siRNA, and resulted either in increased cell death and apoptosis, reduced growth (in VCaP
organoids), or in measurable phenotypic effects in 3D cultures (PC3 organoids). In VCaP
cells, silencing of RHOU, LMNB1, CACNA1D and TDRD1 increased the number of dead cells
detectable by the NucView apoptosis assay, or by incorporation of Ethidium homodimer
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(Table 8). In addition, DLX1 and PLA2G7 also resulted in reduced organoid growth, as mea-
sured by the CellTiter-Glo assay (Table 7).
In most cases, gene silencing in PC3 cells resulted only in minor cytotoxicity, reduction of
tumor cell growth and proliferation, and none induced apoptosis prominently. The strongest
proliferation-blocking effects in PC3 organoids were observed for DLX1, followed by PLA2G7
and RHOU. DLX1 is a homebox domain transcription factor of largely unknown function, pre-
sumably regulating the (de-) differentiation and integrity of epithelial tissues. Overexpression
of DLX1 in CD26+ prostate cancer cells compared to luminal cells has been shown [45]. DLX1
was only recently identified as overexpressed in many PCas [46], an observation that was now
independently confirmed by the new study of Leyton et al, [44] and our own work.
In contrast, PLA2G7, RHOU, ACSM1, LAMB1 and CACNA1D silencing resulted mainly in
altered cell motility and invasion into the surrounding ECM, with PLA2G7 and RHOU being
the most effective. Block of 3D tumor cell invasion coincided with anti-proliferative effects.
The effective reduction of cell-motility, combined with a variable degree of cytotoxicity after
siRNA knock-down was independently confirmed for PLA2G7 and RHOU in 2D wound heal-
ing assays, but not ACSM, LAMB1 and CACNA1D. Both PLA2G7 and RHOU genes might be
involved in migration-promoting processes. Their specific functions could be related to altering
polymerization or contractile properties of the actin cytoskeleton. These processes are more
prominent and relevant for collective invasion in 3D culture, but less important for the differ-
ent modes of cell motility shown in 2D culture on plastic surfaces (amoeboid motility, associ-
ated with the formation of lamellipodia and filopodia). RHOU is one of the less well-known
members of the Rho-family GTPase. Like other Rho family proteins, RHOUmight also have
complex functions in re-arrangement of the actin cytoskeleton, promoting cell-cell adhesion
and migration, vesicle trafficking, or regulation of the cell cycle [47]. The ubiquitous role of
Rho GTPases in malignant progression is widely established [48]. RHOU is an atypical Rho
family member with high homology to CDC42, but contains unique N- and C-terminal exten-
sions. The RHOU gene was shown to be more efficient than the related Cdc42 in triggering
the formation of filopodia and membrane blebbing. RHOU also interacts with Rho-Kinases
(ROCK) and other modulators of actin cytoskeleton integrity, like PAK1 and NCKbeta [49].
RHOU is also functionally linked to Notch1 signaling in leukaemia, where T-ALL cell migra-
tion is stimulated by RHOU upregulation, leading to enhanced motility and dissemination of
leukaemia cells [50]. RHOU was further associated with EGF Receptor (EGFR) signaling. It co-
localizes and physically associates with activated EGFR; thus leading to AP1 transcriptional
activity and effectively promotes migration in pancreatic cancer cells [51]. Similar effects could
promote the aggressive and invasive properties of advanced PCas.
Also silencing of CACNA1D resulted in morphologic effects and a block of invasive struc-
tures, combined with growth inhibition. CACNA1Dmay simultaneously promote PCa cell
growth and proliferation [36], and thus play a generalized, supporting role in castration-resis-
tant cancer progression [37]. As for TDRD1 and PLA2G7, progression-associated overexpres-
sion of CACNA1Dmay be largely independent of ERG-status in these cancers, and apparently
occurs also in ERG-negative cancers. Silencing of LMNB1 and ACSM1 had only relatively weak
morphologic and invasion-blocking effects. ACSM1 has not been previously associated with
PCa progression, but was reported as a potential marker for the invasive apocrine subtype of
breast cancer [52], a rare subtype that is associated with AR+ status and poor differentiation.
Unfortunately, the SPON2 gene was not expressed in PC-3 cells, and could therefore not be
included in functional validation studies. Nevertheless, overexpression of SPON2 PCa samples
and cell lines have been reported previously [53]. Most importantly, increased levels of of
SPON2 protein in serum measured by immunoassay shows better diagnostic performance
compared to sarcosine and free-to-total and total PSA levels in serum [34]. Furthermore,
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elevation of serum SPON2 level in PCa patients and its potential to avoid some of the problems
of PSA testing due to higher sensitivity and specificity have been documented before [54]. Also
hypomethylation of the SPON2 gene promoter in PCa samples compared with normal samples
was reported [55].
In summary, this study provides promising evidence that bioinformatics data mining com-
bined with clinical biomarker validation by qRT-PCR and functional evaluation of candidate
genes in disease-relevant processes can be a highly beneficial means to identify novel biomark-
ers. We have used here siRNA silencing studies to cover all eight target genes across several cell
lines. Additional, more detailed functional studies could make use of more precise, but also
more time consuming genome editing technologies such as TALENS or CRISPR/Cas9 technol-
ogies. This can be considered for detailed follow-up studies on selected candidates in the near
future. The eight novel biomarkers studied here show the potential to become useful biomark-
ers for PCa diagnosis. They may help to improve the timely management of PCa, and support
identification of progression to CRPC.
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